An important consideration for patients with large CMN, particularly those located over the lower spine with satellite nevi, is evaluation for neurocutaneous melanosis (NCM)
Adam, J
However, several developments may affect your options: OSA coverage continues for Medicare members meeting criteria (AHI 15, BMI 30, no diabetes) Oral Wegovy launched January 2026 Available via NovoCare at $149-299/month, no injection required Medicare $50/month benefit Expected mid-2026 for qualifying obesity medications (may not include Humana Medicare Advantage) Medicaid expansion Some states adding GLP-1 coverage
Real-time FDA peptide status monitoring ensures that every compound dispensed aligns with current regulatory allowances, protecting both providers and patients
[1] [2] The medication works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
